番茄红包扫雷游戏开发interpace biosciences, inc. (nasdaq: idxg) today announced that the center for medicare and medicaid services (cms) has modified the reimbursement for interpace diagnostics’ thyramir® mirna classifier for evaluating indeterminate thyroid nodules retroactively to january 1, 2020. this determination increases the medicare reimbursement for thyramir® from approximately $1800 to $3000 reflecting a re-evaluation of the technical
onkos surgical® is pleased to announce the launch of genvie™ magnesium bone scaffold, a novel biologic technology that further expands onkos’ reach in complex limb salvage procedures. genvie is the first 510(k) cleared magnesium-based bone void filler in the orthopaedic marketplace and is available via a private label distribution agreement with bone solutions inc. (osteocrete®)
centurion service group, a leader in medical equipment solutions, announced today that it has acquired salt lake city, ut monet medical, an advanced refurbisher of best-in-class beds, stretchers, infusion pumps and other medical equipment with strong ties to major national medical distributors. originally a medical equipment auction house, centurion service group has firmly cemented its
番茄红包扫雷游戏开发biocoat, inc., a specialty manufacturer of hydrophilic biomaterial coatings for medical devices, today announced the launch of hydak® uv. the new version of its original hydak® coating is designed to be cured using ultraviolet (uv) light, allowing for flexible integration with industry standard uv coating systems. the innovative coating is built on the proven bi-laminar
番茄红包扫雷游戏开发interpace biosciences , inc. (nasdaq: idxg) (“interpace”) a leader in enabling personalized medicine, is pleased to announce today that ron rocca, president & ceo of exagen, inc. (nasdaq: xgn) has been appointed to the interpace board of directors. ron has significant experience as a senior executive at companies which develop and market high value, proprietary
misonix, inc. (nasdaq: mson) (“misonix” or the “company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced the pricing of an underwritten public offering of 1,625,000 shares of its common stock at a price to the public of $18.50 per share. the gross proceeds from this
greenbrook tms neurohealth centers, one of the leading providers of transcranial magnetic stimulation (tms) therapy in the united states, announced today that it is now offering brainsway’s deep tms therapy for patients with obsessive-compulsive disorder (ocd) at its greenbrook – cary facility in north carolina.
番茄红包扫雷游戏开发onkos surgical, inc. a leader in the field of musculoskeletal oncology and personalized orthopaedics announced today a multi-year agreement with integrum ab (integ b: nasdaq first north exchange). the collaboration between companies will commence immediately and will be focused on expanding the us market for integrum’s opra™ (osseoanchored prostheses for the rehabilitation of amputees) implant
番茄红包扫雷游戏开发greenbrook tms neurohealth centers, one of the leading providers of mental health services in the united states, is now offering brainsway’s deep transcranial magnetic stimulation (deep tms) therapy for patients with obsessive-compulsive disorder (ocd) at their newport news location in virginia. other greenbrook locations in the state, including tysons corner and glen allen, have also
番茄红包扫雷游戏开发greenbrook tms inc. (tsx: gtms) (“greenbrook” or the “company”) will release its 2019 fourth quarter and year end operational and financial results after market hours on march 10, 2020.